胃癌患者组织及血清中Periostin的表达情况及其意义探讨

Patients with Gastric Cancer Tissue and Serum Periostin Expression and Its Significance

目的检测胃癌患者癌组织及血清中Periostin蛋白的表达情况,初步探讨其临床意义。方法选择60例唐山市中医医院确诊为胃腺癌的患者癌组织标本、癌旁组织标本及血清,同时选择60例健康体检人员血清标本。所有患者按病例临床因素分类,包括年龄、性别、TNM分期、浸润程度、淋巴结转移情况及病理分级,免疫组化方法测定胃癌组织及癌旁组织中Periostin蛋白的表达情况,酶联免疫法检测胃癌患者及正常患者血清中Periostin蛋白的含量。结果 ELISA法检测发现胃癌患者血清Periostin蛋白水平为46.7±6.4 ng/ml,而健康人群的Periostin蛋白水平为23.1±4.5 ng/ml,差异具有统计学意义(t=7.34,P<0.05);免疫组化方法检测显示胃癌患者癌组织Periostin蛋白阳性率为(73.2±5.4)%,癌旁组织中的阳性率(33.4±6.5)%,差异具有统计学意义(t=8.52,P<0.05);Ⅲ~Ⅳ期患者血清Periostin蛋白水平为64.9±6.3 ng/ml,Ⅰ~Ⅱ期患者血清Periostin蛋白水平为41.6±4.1 ng/ml,差异具有统计学意义(t=9.17,P<0.05);Periostin蛋白在Ⅲ~Ⅳ期患者癌组织中的阳性率为67.8%,Ⅰ~Ⅱ期患者阳性率52.9%,差异具有统计学意义(t=9.64,P<0.05);根据浸润程度分级:T3~T4患者血清Periostin蛋白水平为61.9±6.6 ng/ml,T1~T2患者血清Periostin蛋白水平为44.6±3.7 ng/ml,差异具有统计学意义(t=8.24,P<0.05);Periostin蛋白在T3~T4患者癌组织中的阳性率为66.2%,T1~T2患者阳性率为51.4%,差异具有统计学意义(t=7.58,P<0.05);淋巴结转移组患者血清Periostin蛋白水平为65.2±4.3 ng/ml,无转移患者血清Periostin蛋白水平为42.6±3.2 ng/ml,差异具有统计学意义(t=7.63,P<0.05);Periostin蛋白在淋巴结转移组患者癌组织中的阳性率为60.8%,无转移患者阳性率为37.5%,差异具有统计学意义(t=8.56,P<0.05)。结论 Periostin蛋白在胃癌患者组织及血清中表达显著高于健康人群,且一定程度与病情呈正比,Periostin蛋白是一种可预测胃癌发生、病变程度的潜在生物学指标。

Objective To detect patients with cancer of the stomach cancer tissue and serum Periostin protein expression of the situation,the preliminary explore its clinical significance. Methods Selected 60 cases of our hospital diagnosed as gastric carcinoma patients with carcinoma tissue samples,tissue adjacent to carcinoma specimens and serum,and choose 60 cases of healthy check-up serum specimens at the same time. Classified all patients according to clinical classification factors, inclu- ding age, sex, TNM stage, degree of infiltration, lymph node metastasis and pathological grading, immunohistochemical method determination of Periostin in gastric cancer and adjacent tissue protein expression, enzyme-linked immunoassay detection in patients with gastric cancer patients and normal serum Periostin protein content. Results The method of EI.ISA to detect gastric cancer patients serum Periostin protein level was 46.76.4 ng/ml,and healthy crowd Periostin protein levels was 23. 1 ±4.5 ng/ml, statistically significant difference （t= 7.34, P〈0.05）. Immunohistochemical methods showed that Periostin in patients with cancer of the stomach cancer tissue protein positive rate was （73.2±5.4） %,positive rate of （33.4±6.5） in the tissue adjacent to carcinoma, statistically significant difference （t = 8.52, P〈0.05）.Ⅲ-Ⅳ period patients serum Periostin protein level was 64.9±6.3 ng/ml, Ⅰ -Ⅱ period patients serum Periostin protein level was 41.6±4.1 ng/ml, statistically significant difference （t=9.17, P〈 0.05）. Periostin protein in Ⅲ-Ⅳ positive rate was 67.8% in patients withcarcinoma tissue, Ⅰ- phase Ⅲ positive rate was 52.9 %, statistically significant difference （t= 9.64, P〈0.05）. According to infiltrate the classification： T3 ,T4 patients serum Periostin protein level was 61.9 ± 6.6 ng/ml, T1 and T2 patients serum Periostin protein level was 44.6±3.7 ng/ml, statistically significant difference （t= 8.24, P〈0. 05）. Periostin protein in T3 and T4 positive rate was 66.2% in patients with carcinoma tissue,T1 and T2 positive rate was 51.4%,statistically signifi- cant difference （t= 7.58,P〈0.05）. Lymph node metastasis patients serum Periostin protein level was 65.2 ± 4.3 ng/ml, without metastasis in patients with serum Perlostin protein level was 42.6±3.2 ng/ml,statistically significant difference （t = 7.63,P〈0.05）. Periostin protein in the tissue of carcinoma patients with lymph node metastasis group positive rate was 60.8% ,no transfer of positive rate was 37.5% ,statistically significant difference （t=8.56,P〈0. 05）. Conclusion Periostin protein expression in patients with gastric cancer tissue and serum was significantly higher than that of healthy people, and to a certain extent is proportional to the illness, Periostin protein is a predictable stomach occurrence,lesion degree of potential biological indicators.